Table 2.
Characteristics of the Study Population
| Characteristic | Dyspnea | p | |
|---|---|---|---|
| No (n=198) | Yes (n=101) | ||
| Gender, n (%) | |||
| Male | 147 (74.3) | 73 (72.3) | 0.763 |
| Female | 51 (25.7) | 28 (27.7) | |
| Age, years, median (range) | 64 (42–88) | 66 (32–90) | 0.087 |
| BMI, kg/m2, median (range) | 21 (21–50) | 20 (28–45) | 0.976 |
| MI, n (%) | |||
| NSTEMI | 87 (44.4) | 47 (47.5) | 0.887 |
| STEMI | 110 (55.6) | 53 (52.5) | |
| CAD, n (%) | |||
| One-vessel | 64 (32.8) | 31 (31.3) | |
| Two-vessel | 65 (33.3) | 41 (41.4) | 0.344 |
| Three-vessel | 66 (33.8) | 27 (27.3) | |
| DM, n (%) | 25 (12.7) | 17 (17.0) | 0.940 |
| Hypothyroidism, n (%) | 3 (1.5) | 6 (5.9) | 0.066 |
| AF, n (%) | 25 (12.7) | 17 (17.0) | 0.411 |
| Troponin I, ng/mL | 511 (20–89,977) | 533 (20–104,099) | 0.735 |
| Troponin I after 6 h, ng/mL | 8703 (20–635,352) | 4610 (20–147,527) | 0.148 |
| BNP, pmol/l | 128 (11–1858) | 130 (6–2000) | 0.996 |
| BNP after 3 months, pmol/l | 62 (9–381) | 51 (5–300) | 0.527 |
| ADP HS, U | 25 (9–147) | 19 (2–133) | <0.001 |
| ADP HS after 3 months, U | 23 (9–58) | 20 (1–79) | 0.005 |
| Creatinine, mol/L | 80 (42–480) | 85 (41–182) | 0.012 |
| GFR (mL/min/1.73m2) | 83.7 (10.4–188.2) | 79.7 (32.6–190.4) | 0.028 |
| CRP, mg/l | 6.8 (0.3–146) | 6 (0.3–179.4) | 0.663 |
| LDL-C, mmol/l | 3.5 (1.4–7.8) | 3.5 (1.4–7.1) | 0.430 |
| Hemoglobin, g/l | 143 (93–387) | 142 (85–345) | 0.753 |
| LVEF, % | 50 (15–55) | 50 (20–55) | 0.458 |
| Medications, n (%) | |||
| Beta blockers | 192 (97.5) | 97 (96.0) | 0.494 |
| ACE inhibitors | 192 (97.5) | 98 (97.0) | 1.000 |
| Statins | 196 (99.5) | 99 (98.0) | 0.266 |
| Anticoagulants | 22 (11.2) | 15 (15.0) | 0.345 |
Notes: Values are median (range) unless indicated otherwise.
Abbreviations: BMI, body mass index; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction; CAD, coronary artery disease; DM, diabetes mellitus; AF, atrial fibrillation; BNP, B-type natriuretic peptide; ADP HS, platelet aggregation with high-sensitivity ADP; GFR, glomerular filtration rate; LDL-C, low-density lipoprotein cholesterol; CRP, C-reactive protein; LVEF, left ventricular ejection fraction; ACE, angiotensin-converting enzyme.